Dyadic International, Inc. earnings per share and revenue
On Nov 12, 2025, DYAI reported earnings of -0.06 USD per share (EPS) for Q3 25, missing the estimate of -0.04 USD, resulting in a -35.75% surprise. Revenue reached 1.17 million, compared to an expected 1.12 million, with a 3.83% difference. The market reacted with a -3.87% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 1.37 million USD, implying an decrease of -33.33% EPS, and increase of 17.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Dyadic International, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Dyadic International, Inc. reported EPS of -$0.06, missing estimates by -35.75%, and revenue of $1.17M, 3.83% above expectations.
How did the market react to Dyadic International, Inc.'s Q3 2025 earnings?
The stock price moved down -3.87%, changed from $0.94 before the earnings release to $0.91 the day after.
When is Dyadic International, Inc. expected to report next?
The next earning report is scheduled for Mar 24, 2026.
What are the forecasts for Dyadic International, Inc.'s next earnings report?
Based on 4
analysts, Dyadic International, Inc. is expected to report EPS of -$0.04 and revenue of $1.37M for Q4 2025.